1 / 18

Douche as Microbicide Vehicle: Safety, Pharmacokinetics, Acceptability of 3 Candidates

Douche as Microbicide Vehicle: Safety, Pharmacokinetics, Acceptability of 3 Candidates. Craig W. Hendrix, MD Johns Hopkins University NIH Grant IP/CP U19 AI060614. Objectives. Determine a relatively safe enema for use in future rectal microbicide development

rockwell
Download Presentation

Douche as Microbicide Vehicle: Safety, Pharmacokinetics, Acceptability of 3 Candidates

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Douche as Microbicide Vehicle: Safety, Pharmacokinetics, Acceptability of 3 Candidates Craig W. Hendrix, MD Johns Hopkins University NIH Grant IP/CP U19 AI060614

  2. Objectives • Determine a relatively safe enema for use in future rectal microbicide development • Explore the feasibility of an enema as rectal microbicide delivery vehicle

  3. Definitions • Osmosis:movement of solvent molecules (molecules in which solute is dissolved) through selectively-permeable membrane toward higher solute concentration, equalizing the solute concentrations • Osmotic pressure: pressure needed to prevent the inward flow of water across a semipermeablemembrane (e.g., cell, colon lining) • Osmole: number of moles of a chemical that contribute to a solution's osmotic pressure (e.g., NaCl, 1 mole, but 2 osmoles) • Osmolarity: osmoles per liter • Osmolality: osmoles per kilogram • Tonicity: takes account of onlynon-penetrating solutes (osmolarity considers both penetrating & non-penetrating solutes) • Hyperosmolar: causes cells to shrink, draws water into fluid • Iso-osmolar: no change in cell water, no water flow into fluid • Hypo-osmolar: causes cells to swell, water flow out of fluid

  4. Background • Rectal douching (enema) prior to receptive analintercourse (RAI) common among men who practice unprotected RAI (Carballo-Dieguez 2007, Hylton 2007) • Rectal douching associated with increased risk for HIV transmission (Coates 1988, Moss 1988) • Tap water (hypo-osmolar) and Fleet (hyper-osmolar) enema most commonly used (Hylton 2007) • Tap water & hyper-osmolar enemas show colonic epithelium damage (Meisel 1977, Schmelzer 2004) • Rectal hyper-osmolar gels induce greater epithelial loss than iso-osmolar gels (Fuchs 2007)

  5. Study Design • Randomized, blinded, comparative study • Population: 9 HIV negative MSM • Study Products: 125 mL rectal douche (enema) varying osmolality: • Fleet (HYPER), • Tap water (HYPO), • Normosol-R™ balanced salt solution (ISO) • Doses: 1 inpatient radiolabeled dose and 3 outpatient doses (used in the context of RAI) for each of the 3 products

  6. Outcome Measures • Distribution/retention: • SPECT/CT imaging of radiolabeled enema • 2 and 24 hours after dose • Toxicity • Colon biopsy 2 hours after dose • Permeability for 24 hours after dose • Acceptability: • questionnaires after each dose, each product phase, and end of study • structured interviews at study end

  7. SPECT/CT Distribution • Single Photon Emitted Computed Tomography/CT • Radiolabeled products appear in color (SPECT) • Anatomy appears in grayscale (CT) • Views: coronal (front), sagittal (from left), axial (below) • HYPERdistributes into rectosigmoid (further in this subject than in any other, most of which lost all signal or were restricted to rectum) • ISOdistributes throughout the distal colon up to the splenic flexure (seen with ISO product in most subjects).

  8. HYPER ISO

  9. SPECT Distribution • MIP: Maximal intensity projection, full thickness of SPECT scan unlike single slice in prior views • “Coronal” view from subject’s front • “Sagittal” view from subject’s left • Distribution: • begins in rectum • up, forward through sigmoid colon • left and up through the descending colon • up to the splenic flexure. MIP Sagittal MIP Coronal

  10. HIV Distribution Cell-free HIV Surrogate 99mTc-Sulfur Colloid Cell-Associated HIV Surrogate 111In-Lymphocytes MIP SPECT/CT SPECT/CT MIP • Same distribution of cell-free and cell-associated surrogates • Consistently within rectum and lower sigmoid colon

  11. 400 300 200 100 0 HYPER HYPO ISO Enema Volume • Volume of enema on SPECT @ 2 hrs • Boxplots: median (bar), middle 50% (box) • Significantly greater retained volume of ISO compared to HYPER. • Quantitative assessments for proximal distribution, volume retained, and residual concentration were all significantly greater for ISO compared to HYPER with HYPO intermediate (data not shown). p<0.05

  12. Colon Biopsy • Iso-osmolar (10x, H&E) • Healthy epithelial lining with single columnar cells rich with mucin across the surface (Grade 0). • Hyper-osmolar (10x, H&E) • Right section indicates loss of epithelial columnar cells, except in crypts, leaving exposed lamina propria cells (Grade 3).

  13. 3 2.5 2 2 1.5 1 1 .5 0 0 Baseline Baseline HYPER HYPER HYPO HYPO ISO ISO Epithelial Changes Epithelial Denudation * Average score • HYPER enema significantly greater compared to baseline, HYPO, ISO. • Histologic score: % of fields with finding, 0% (Grade 0) to >67% (Grade 3) Lamina Propria Hemorrhage *HYPER v. each of the other 3, p<0.01 * Average score *HYPER v. each of the other 3, p<0.03

  14. Permeability

  15. Brief Acceptability

  16. Product Acceptability

  17. Summary & Impact • HYPER • greatest epithelial loss and hemorrhage • concern for transmission risk? • HYPO • greatest permeability • enhance active drug ingredient tissue penetration? • ISO • greatest distribution/retention/concentration • least toxicity • trend to more favorable acceptability • candidate for microbicide delivery vehicle?

  18. Acknowledgments • Johns Hopkins • Edward Fuchs • Elizabeth Purdy • Rahul Bakshi • Francisco Leyva • Kathleen Truelove • Linda Lee • Michael Torbenson • Brian Caffo • Microbicide Development Program • Peter Anton • Elena Khanukhova • NIH (IPCP U19 AI060614) • Jim Turpin • Jeanna Piper • Cherlynn Mathias • Roberta Black

More Related